# EDGAR Filing Document

**Accession Number:** 0001944885
**File Stem:** 0000000000-23-001680
**Filing Date:** 2023-2
**Character Count:** 6310
**Document Hash:** aeffb57b662a91bfdd67c993be96f830
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001680.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0000000000-23-001680

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230217

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apollomics Inc.
- **CENTRAL INDEX KEY:** 0001944885
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 989 EAST HILLSDALE BLVD.
- **STREET 2:** STE 220
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 1-650-209-4055

**MAIL ADDRESS:**
- **STREET 1:** 989 EAST HILLSDALE BLVD.
- **STREET 2:** STE 220
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950123-22-009989

## Text-Extract

```

United States securities and exchange commission logo

                             February 17, 2023

       Guo-Liang Yu
       Chief Executive Officer
       Apollomics Inc.
       989 E. Hillsdale Blvd., Suite 220
       Foster City, CA 94404

                                                        Re: Apollomics Inc.
                                                            Amendment No. 3 to
Registration Statement on Form F-4
                                                            Filed February 10,
2023
                                                            File No. 333-268525

       Dear Guo-Liang Yu:

              We have reviewed your amended registration statement and have the
following
       comment. In our comment, we may ask you to provide us with information
so we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 3 to Registration Statement on Form F-4

       Summary of the Proxy Statement/Prospectus
       Subscription Agreements, page 36

   1.                                                   We note that certain
accredited investors have entered into subscription agreements to
                                                        purchase Apollomics
Class B Ordinary Shares and Apollomics Series A Preferred Shares
                                                        in connection with the
business combination. Please further highlight the material
                                                        differences in the
terms and price of securities issued at the time of the IPO as compared
                                                        to private placements
contemplated at the time of the business combination. Please also
                                                        disclose if any of
Maxpro's sponsors, directors, officers or their affiliates will
                                                        participate in this
private placement.
 Guo-Liang Yu
FirstName
ApollomicsLastNameGuo-Liang Yu
           Inc.
Comapany17,
February  NameApollomics
            2023         Inc.
February
Page 2 17, 2023 Page 2
FirstName LastName
       You may contact Christine Torney at 202-551-3652 or Kevin Vaughn at
202-551-3494 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Tyler Howes at 202-551-3370 or Suzanne Hayes at 202-551-3675 with any
other
questions.

                                                         Sincerely,

                                                         Division of
Corporation Finance
                                                         Office of Life
Sciences
cc:      Daniel Nussen, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 17, 2023

Guo-Liang Yu  
Chief Executive Officer  
Apollomics Inc.  
989 E. Hillsdale Blvd., Suite 220  
Foster City, CA 94404

**Re: Apollomics Inc.**

**Amendment No. 3 to Registration Statement on Form F-4**

**Filed February 10, 2023**

**File No. 333-268525**

Dear Guo-Liang Yu:

We have reviewed your amended registration statement and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Amendment No. 3 to Registration Statement on Form F-4

Summary of the Proxy Statement/Prospectus

Subscription Agreements, page 36

1. We note that certain accredited investors have entered into subscription agreements to purchase Apollomics Class B Ordinary Shares and Apollomics Series A Preferred Shares in connection with the business combination. Please further highlight the material differences in the terms and price of securities issued at the time of the IPO as compared to private placements contemplated at the time of the business combination. Please also disclose if any of Maxpro's sponsors, directors, officers or their affiliates will participate in this private placement.

Guo-Liang Yu
Apollomics Inc.
February 17, 2023
Page 2

You may contact Christine Torney at 202-551-3652 or Kevin Vaughn at 202-551-3494 if you have questions regarding comments on the financial statements and related matters. Please contact Tyler Howes at 202-551-3370 or Suzanne Hayes at 202-551-3675 with any other questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Daniel Nussen, Esq.